FRANCHISE TRADE NOW OPEN AN ACCOUNT GLOBE E-KYC
Hot Pursuit
Prev Next
As on Jun 27, 2017 12:00 AM Your results on : Hot Pursuit    
Cadila Healthcare gets stronger after board approves fund raising
27-Jun-2017 (10:26)
The announcement was made on Monday, 26 June 2017. The market was shut on Monday, 26 June 2017, on account of holiday.

Meanwhile, the S&P BSE Sensex was down 69.45 points, or 0.22% to 31,072.69.

On the BSE, 34,702 shares were traded in the counter so far, compared with average daily volumes of 1.54 lakh shares in the past one quarter. The stock had hit a high of Rs 535.35 and a low of Rs 527.45 so far during the day. The stock had hit a record high of Rs 558 on 12 June 2017. The stock had hit a 52-week low of Rs 305.05 on 24 June 2016.

The stock had outperformed the market over the past one month till 23 June 2017, gaining 19.03% compared with 2.55% rise in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 17.5% as against Sensex's 6.16% gains. The scrip had also outperformed the market in past one year, jumping 66.83% as against Sensex's 15.32% gains.

The large-cap company has equity capital of Rs 102.37 crore. Face value per share is Re 1.

Cadila Healthcare said that its board approved in-principle to raise funds by issue of equity shares/ convertible bonds/debentures through qualified institutional placement (QIP)/ global depository receipts (GDR)/American depository receipts (ADR), for an aggregate amount up to Rs 10000 crore.

The board also approved to issue secured/unsecured redeemable non-convertible debentures/foreign currency bonds on private placement basis for an amount up to Rs 3500 crore in the financial year 2017—2018. Further, the board also approved to issue foreign currency bond/foreign currency convertible bonds for an amount up to Rs 5000.

Separately, Cadila Healthcare announced that it has received final approval from the United States Food & Drug Administration (USFDA) to market Entecavir Tablets in the strengths of 0.5 mg and 1 mg. The announcement was made during market hours today, 27 June 2017.

The drug is used in the treatment of Hepatitis B virus infection and will be produced at the group's formulations manufacturing facility at the Pharma special economic zone (SEZ) in Ahmedabad. The estimated sale of Entecavir Tablets in US is $166.3 million as per the IMS MAT April 2017.

Cadila Healthcare's consolidated net profit fell 32.2% to Rs 385.5 crore on 6.5% rise in net sales to Rs 2417.50 crore in Q4 March 2017 over Q4 March 2016.

Cadila Healthcare is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies.

Apollo Tyres declines ex-dividend
27-Jun-2017 (09:40)
Infibeam gains on stock-split plan
27-Jun-2017 (09:31)
LT Foods boils after announcing inauguration of rice plant
27-Jun-2017 (09:24)
Punj Lloyd declines on profit booking
23-Jun-2017 (15:17)
Reliance Infra gains on transport biz spin-off plan buzz
23-Jun-2017 (15:01)
Apcotex Industries drops after recent sharp rally
23-Jun-2017 (14:57)
Wockhardt gets healthier after settling dispute with Teva
23-Jun-2017 (14:30)
Indiabulls Real Estate surges on fund raising proposal
23-Jun-2017 (14:19)
Fortis Healthcare leads losers on BSE's 'A' group
23-Jun-2017 (13:56)
Volumes jump at HCG counter
23-Jun-2017 (13:47)
Quess Corp gains on acquisition pact
23-Jun-2017 (12:43)
Fortis Healthcare slumps after buzz of IHH denying stake buy
23-Jun-2017 (12:32)
Bharat Bijlee drops on profit booking
23-Jun-2017 (12:28)
Prabhat Dairy slides on profit taking
23-Jun-2017 (12:14)
Indian Metals spurts after pollution board's nod for mines
23-Jun-2017 (11:28)
Reliance Defence extends gains
23-Jun-2017 (11:10)
Deep Industries advances after winning contract
23-Jun-2017 (10:50)
DFM Foods declines after recent sharp rally
23-Jun-2017 (10:34)
Graphite India slips on profit booking
23-Jun-2017 (10:12)
Connect with us :   
Globe
About us
Our Services
Milestones
Memberships
Core Values
Investor Relations
Product & Services
Broking
Institutional Broking
PMS
Clearing Services
Distribution
Research
Depository
Trade & Products
Globe Connect Pro
Globe Trade Smart
Globe Connect Mobile/Tablet
Globe News Connect
Globe e-KYC Application
Back Office
Back Office
CMS
CMS-TM
KYC/KDC Status
Mutual Fund
CAMS
RMS Policy
Helpdesk
Download Forms
Useful Links
BSE
NSE
SEBI
RBI
MCX
NCDEX
Exchange Holidays
Policies, Procedures, Rights, Obligations and RDD
Guidance Note on FATCA and CRS May 2016
Right and Obligation, RDD, Guidance Note in Vernacular Language
In case of any grievances pleae write to
Investor_trading@globecapital.com /  igr@globecapital.com (For Trading)     globedp@globecapital.com (For DP)    Investor_pms@globecapital.com (For PMS)     
commigr@globecapital.com (For Commodities)
SEBI Regn. No. NSE.:INB/INF/INE 230663732, TM No.:06637, Clearing No.- M50302 | SEBI Regn. No. BSE.:INB/INF/INE 010663731, Clearing No.- 3179 | SEBI Regn No. MSEI :INB/F 260663738, INE 260663732, TM Code-1004, Clearing Member Code- 4 | USE SEBI Regn no. - INE 270663732 , CM code: 06637 | SEBI Regn for DP : IN-DP-NSDL-97-99, NSDL- DP ID: IN300966, CDSL DP ID: 12020600 | Research Analysts Regn No. INH100001187 | PMS Regn No. INP000002361
* Through subsidiary Globe Commodities Ltd. --> Commodity Membership No.: NCDEX- FMC Regn. No. NCDEX/TCM/CORP/0004, TM Code-00012 | MCX- FMC Regn. No. MCX/TCM/CORP/0628, CM Code-8550 | ICEX- FMC Regn. No. ICEX/TCM/CORP/0011, TM Code- 1009 | NMCE- FMC Regn. No. NMCE/TCM/CORP/0018, TM Code-CL0111 | ACE - FMC Registration no.- ACEL/TCM/CORP/0163, TM code- 4001 | UCX FMC Regn. No.: UCX/TCM?CORP/0014, TM Code- 10014 | NCDEX Spot Exchange Membership no.- NCDEXSPOT-CR-07-10011
** Through step in subsidiary Globe Comex International DMCC --> DGCX **TM Id.1064, CM Id.3064*
"We also do Pro-Account trading in Commodity Segment.."
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
Attention Investors:
"Prevent Unauthorised transactions in your account --> Update your mobile numbers/email IDs with your Stock Brokers. Receive information of your transactions directly from Exchange on your mobile/email at the end of the day .......... Issued in the interest of investors"
"Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from NSDL/CDSL on the same day......................issued in the interest of investors."
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
© 2013 Globe Capital Market Limited. All rights reserved
Designed, Developed and Content powered by C-MOTS Infotech (ISO 9001:2008 Certified) Privacy Policy Disclaimer Terms and Conditions